2023年无创正压通气临床研究进展
本文通过Medline检索2022年10月1日至2023年9月30日期间无创正压通气(NPPV)相关临床研究文献进行综述。综述涵盖新冠肺炎相关及非新冠肺炎相关急性呼吸衰竭、撤机序贯NPPV、湿化与不同无创呼吸支持策略选择等热点,汇总了各研究关于疗效比较、预测评分验证及临床应用潜力的主要发现。
要点
- 轻中度ARDS比重度ARDS更适合NPPV,重度ARDS延迟插管风险增加。
- 严重呼吸困难者NPPV较HFNC和普通氧疗获益更大,自发性肺损伤风险降低。
- 更新版HACOR评分和ROX评分对低氧性ARF患者NPPV治疗失败有较高预测价值。
核心结论
- NPPV在不同病因急性呼吸衰竭及撤机序贯治疗中具有重要价值,但需根据患者病因和病情严重程度选择呼吸支持策略。
- 轻中度ARDS患者更适合NPPV,重度ARDS患者应用NPPV存在延迟插管风险。
研究设计与样本
- 综述通过Medline检索2022年10月1日至2023年9月30日期间发表的NPPV相关临床研究文献。
主要发现
- 在新冠肺炎相关ARF中,地区经济状态对呼吸支持策略选择有较大影响。
- 轻中度ARDS比重度ARDS患者更适合应用NPPV。
- 严重呼吸困难者应用NPPV较HFNC和普通氧疗获益更大,自发性肺损伤风险降低。
- 非新冠肺炎相关高碳酸性ARF患者中,HFNC与NPPV的疗效无明显差异。
- 早期撤机序贯NPPV比传统撤机方法患者病死率更低,NPPV联合主动湿化比HFNC显著提高撤机失败非常高危患者的撤机成功率。
关键数值与推荐
- 更新版HACOR评分和ROX评分预测低氧性ARF患者NPPV治疗失败的准确性较高。
临床怎么用
- 临床选择NPPV或HFNC应基于患者具体病因。
- 撤机后不同人群应选择不同的无创呼吸支持策略。
- 对低氧性ARF接受NPPV治疗者,可应用更新版HACOR评分和ROX评分预测治疗失败风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-invasive positive pressure ventilation (NPPV) is a widely used method of providing respiratory support in a variety of clinical settings, including emergency departments, general wards, and intensive care units. The relevant research articles on NPPV published between 1st October 2022 and 30th September 2023 were retrieved from Medline and reviewed. In the management of acute respiratory failure (ARF) associated with COVID-19, studies have highlighted the significant influence of regional economic status on the choice of respiratory support strategies. It has been observed that NPPV is more suitable for patients with mild to moderate acute respiratory distress syndrome (ARDS) than for those with severe ARDS, as the latter group has an increased risk of delayed intubation. In addition, patients with severe dyspnea tended to benefit more from NPPV compared with high flow nasal cannula (HFNC) and conventional oxygen therapy, with a reduced risk of self-induced lung injury. For non-COVID-19-related ARF, research shows no significant differences in mortality and intubation rates between HFNC and NPPV in patients with hypercapnic ARF. The updated HACOR score and ROX score have been validated to have a high predictive value for clinical outcomes in patients receiving NPPV for hypoxemic ARF. With regard to weaning from invasive mechanical ventilation, immediate application of NPPV after extubation showed a lower mortality rate compared to continued invasive weaning. Moreover, NPPV with active humidification significantly decreased the reintubation rate within 7 days after extubation compared with HFNC. The choice between using NPPV and HFNC should be based on the specific etiology of the patient's condition. The potential effect of noninvasive high-frequency oscillatory ventilation on CO2 clearance was also investigated. 无创正压通气(NPPV)是临床治疗各类呼吸衰竭患者的常用手段,在急诊、普通病房及ICU等多个治疗场景均有应用。本文通过Medline检索2022年 10月1日至2023年 9月30日期间NPPV相关临床研究的文献进行综述。在NPPV治疗新冠肺炎相关急性呼吸衰竭(ARF)方面,有研究指出地区经济对呼吸支持策略的选择存在较大影响;轻中度ARDS比重度ARDS患者更适合应用NPPV;NPPV在减低严重呼吸困难者的自发性肺损伤比高流量鼻导管氧疗(HFNC)和普通氧疗获益更大。在非新冠肺炎相关ARF方面,有研究指出HFNC和NPPV治疗高碳酸性ARF患者的疗效无明显差异;更新版的HACOR评分和ROX评分预测低氧性ARF患者NPPV治疗失败的准确性较高。在NPPV辅助撤机方面,提出了早期撤机序贯NPPV比传统撤机方法的患者病死率更低、NPPV联合主动湿化比HFNC显著提高撤机失败非常高危患者的撤机成功率、不同人群在撤机后应该选择不同的无创呼吸支持策略的观点。此外,无创高频振荡通气的应用也在提高CO2清除率方面显现出一定的潜力。.
引用
- Zha SS, He ZF, Guan LL, et al. [Clinical research progress in non-invasive positive pressure ventilation in 2023]. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 38309965. doi:10.3760/cma.j.cn112147-20231027-00276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。